314 related articles for article (PubMed ID: 19535262)
1. New mechanisms for PRLr action in breast cancer.
Clevenger CV; Gadd SL; Zheng J
Trends Endocrinol Metab; 2009 Jul; 20(5):223-9. PubMed ID: 19535262
[TBL] [Abstract][Full Text] [Related]
2. CAML promotes prolactin-dependent proliferation of breast cancer cells by facilitating prolactin receptor signaling pathways.
Lim JH; Kim TY; Kim WH; Park JW
Breast Cancer Res Treat; 2011 Nov; 130(1):19-27. PubMed ID: 21128111
[TBL] [Abstract][Full Text] [Related]
3. Prolyl isomerase cyclophilin A regulation of Janus-activated kinase 2 and the progression of human breast cancer.
Zheng J; Koblinski JE; Dutson LV; Feeney YB; Clevenger CV
Cancer Res; 2008 Oct; 68(19):7769-78. PubMed ID: 18829531
[TBL] [Abstract][Full Text] [Related]
4. Structural characterization of the stem-stem dimerization interface between prolactin receptor chains complexed with the natural hormone.
van Agthoven J; Zhang C; Tallet E; Raynal B; Hoos S; Baron B; England P; Goffin V; Broutin I
J Mol Biol; 2010 Nov; 404(1):112-26. PubMed ID: 20875426
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel ligand that activates JAK2/STAT5 signaling through a heterodimer of prolactin receptor and growth hormone receptor.
Langenheim JF; Chen WY
J Recept Signal Transduct Res; 2009; 29(2):107-12. PubMed ID: 19519175
[TBL] [Abstract][Full Text] [Related]
6. Re-evaluation of the prolactin receptor expression in human breast cancer.
Galsgaard ED; Rasmussen BB; Folkesson CG; Rasmussen LM; Berchtold MW; Christensen L; Panina S
J Endocrinol; 2009 Apr; 201(1):115-28. PubMed ID: 19153125
[TBL] [Abstract][Full Text] [Related]
7. Differences in prolactin receptor (PRLR) in mouse and human fallopian tubes: evidence for multiple regulatory mechanisms controlling PRLR isoform expression in mice.
Shao R; Nutu M; Weijdegård B; Egecioglu E; Fernandez-Rodriguez J; Tallet E; Goffin V; Ling C; Billig H
Biol Reprod; 2008 Oct; 79(4):748-57. PubMed ID: 18596217
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer.
Damiano JS; Wasserman E
Clin Cancer Res; 2013 Apr; 19(7):1644-50. PubMed ID: 23515410
[TBL] [Abstract][Full Text] [Related]
9. Prolactin and the prolactin receptor: new targets of an old hormone.
Harris J; Stanford PM; Oakes SR; Ormandy CJ
Ann Med; 2004; 36(6):414-25. PubMed ID: 15513293
[TBL] [Abstract][Full Text] [Related]
10. A novel and functional interaction between cyclophilin A and prolactin receptor.
Syed F; Rycyzyn MA; Westgate L; Clevenger CV
Endocrine; 2003; 20(1-2):83-90. PubMed ID: 12668872
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex.
Xu J; Zhang Y; Berry PA; Jiang J; Lobie PE; Langenheim JF; Chen WY; Frank SJ
Mol Endocrinol; 2011 Apr; 25(4):597-610. PubMed ID: 21310852
[TBL] [Abstract][Full Text] [Related]
12. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice.
Bole-Feysot C; Goffin V; Edery M; Binart N; Kelly PA
Endocr Rev; 1998 Jun; 19(3):225-68. PubMed ID: 9626554
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a novel and functional human prolactin receptor isoform (deltaS1PRLr) containing only one extracellular fibronectin-like domain.
Kline JB; Rycyzyn MA; Clevenger CV
Mol Endocrinol; 2002 Oct; 16(10):2310-22. PubMed ID: 12351696
[TBL] [Abstract][Full Text] [Related]
14. Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications.
Gadd SL; Clevenger CV
Mol Endocrinol; 2006 Nov; 20(11):2734-46. PubMed ID: 16840534
[TBL] [Abstract][Full Text] [Related]
15. GHR/PRLR Heteromultimer Is Composed of GHR Homodimers and PRLR Homodimers.
Liu Y; Zhang Y; Jiang J; Lobie PE; Paulmurugan R; Langenheim JF; Chen WY; Zinn KR; Frank SJ
Mol Endocrinol; 2016 May; 30(5):504-17. PubMed ID: 27003442
[TBL] [Abstract][Full Text] [Related]
16. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.
Dandawate P; Kaushik G; Ghosh C; Standing D; Ali Sayed AA; Choudhury S; Subramaniam D; Manzardo A; Banerjee T; Santra S; Ramamoorthy P; Butler M; Padhye SB; Baranda J; Kasi A; Sun W; Tawfik O; Coppola D; Malafa M; Umar S; Soares MJ; Saha S; Weir SJ; Dhar A; Jensen RA; Thomas SM; Anant S
Gastroenterology; 2020 Apr; 158(5):1433-1449.e27. PubMed ID: 31786131
[TBL] [Abstract][Full Text] [Related]
17. Expression of prolactin and its receptor in human breast carcinoma.
Reynolds C; Montone KT; Powell CM; Tomaszewski JE; Clevenger CV
Endocrinology; 1997 Dec; 138(12):5555-60. PubMed ID: 9389544
[TBL] [Abstract][Full Text] [Related]
18. Prolactin induces up-regulation of its cognate receptor in breast cancer cells via transcriptional activation of its generic promoter by cross-talk between ERα and STAT5.
Kavarthapu R; Tsai Morris CH; Dufau ML
Oncotarget; 2014 Oct; 5(19):9079-91. PubMed ID: 25193864
[TBL] [Abstract][Full Text] [Related]
19. Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness.
Kavarthapu R; Dufau ML
Front Endocrinol (Lausanne); 2022; 13():949396. PubMed ID: 36187116
[TBL] [Abstract][Full Text] [Related]
20. Essential role of endogenous prolactin and CDK7 in estrogen-induced upregulation of the prolactin receptor in breast cancer cells.
Kavarthapu R; Dufau ML
Oncotarget; 2017 Apr; 8(16):27353-27363. PubMed ID: 28423697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]